Compare Mesoblast Limited (MESO) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Rush Street Interactive Inc — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while Rush Street Interactive Inc trades at $19.3 (market cap $2.35B). The key difference: Rush Street Interactive Inc is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 2,219,374). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Rush Street Interactive Inc for 13 Days on average.
| MESO | RSI | |
|---|---|---|
Market Cap | $1.75B | $2.35B |
Volume | 239,027 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $34.52 |
52-Week Low | $13.19 | $15.89 |
Typical Hold Time | 14 Days | 13 Days |
Enterprise Value | $1.83B | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
RSI trades at $19.89, down 1.73% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.15, beating estimates, and revenue growth to $1.4 billion projected for 2026. Analyst consensus is strongly bullish with a $34.88 price target, though net income margins remain thin at 2.33%.
The stock presents a mixed outlook: strong analyst support and revenue growth contrast with high valuation multiples and bearish technical trends. Key risks include competitive pressures in online gaming and reliance on sports betting cycles. Upside depends on margin improvement and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
